🔗 Share this article

As America undertakes historic revisions to its vaccine guidelines, one figure has emerged somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports physician and public health researcher who rose to prominence by expressing skepticism about Covid vaccinations during the global health crisis and has focused upon possible deaths following COVID-19 immunization in her brief tenure at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Program

Health officials planned to reveal major changes to the childhood vaccine schedule recently, aligning the US with the Danish vaccine program, sources say – a significant shift that would place the US out of alignment with much of the global community with insufficient data for benefit. The announcement has been postponed until the next year.

Instead of the director of the vaccine center, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was newly appointed acting director of the FDA’s drug evaluation center, the fifth individual to lead the division this calendar year.

A New Direction at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the drug and vaccine branches as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a greater focus upon reevaluating long-standing vaccines at the FDA.

The new acting director has frequently advocated for halting some childhood vaccine recommendations in the US in order to be more like the Danish model, a nation with comprehensive healthcare and a citizenry about the population of the state of Wisconsin.

In her initial comments, she has continued to focus on vaccines – traditionally the purview of Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Qualifications

The appointee has no apparent background in medication creation, approval processes or leadership, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a senior adviser to the FDA chief and CBER since March.

“She doesn’t seem to have the requisite experience” for running the pharmaceutical oversight division, remarked a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She has no expertise in managing a sizeable institution. She lacks background in drug approvals.”

Former directors of the center would “be deeply familiar with legal statutes and the underlying principles of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that former directors who ran CBER have had.”

This division has an vast workload at the agency, she stated.

“Everybody just pays attention on the novel medication approvals, but the off-patent medication office authorizes thousands of generic medications. There’s a biosimilars division, OTC medication office and other areas, and all of those need to be looked after,” she explained. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a significant administrative element to the role, which supervises in excess of 5,000 personnel. “It is a massive leadership role, if you execute it properly,” she added.

Official Statement and Disputed Programs

Regarding inquiries about Dr. Høeg's qualifications and whether this selection indicates greater collaboration among agency officials on immunizations, a press secretary said that the “inquiries are based on incorrect premises”.

“This background aligns with the duties of her role,” the representative stated, citing the months Dr. Høeg spent counseling the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and shot safety tracking”.

In her interim role, Dr. Høeg takes over the agency head's new expedited review system, a contentious rapid drug-approval program that apparently concerned her preceding directors. “By what process are these drugs being selected for this fast-track system? Who takes the choices?” Dr. Howard asked. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

Broadly speaking, he remarked, “the FDA appears to be shifting towards laxer regulations of all drugs, aside from vaccines.”

Public Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if troubling, past, critics have noted. She authored a study using non-validated public submissions to determine the rate of myocarditis after Covid immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccinations are pose a greater threat than they are.

Among her “desired changes” for the current administration featured altering guidelines for novel immunizations and ending “unnecessary” immunizations, she stated following the vote on a audio program. At the FDA, Dr. Høeg has allegedly proposed excluding young men from getting Covid vaccinations.

“She’s an thorough true believer who begins with her conclusions and reverse-engineers to retrofit the data in a very deceptive, untruthful manner,” Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg became part of fellow skeptics, {like|